- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tumor Ablation Market to Reach $2.1 Billion by 2031
Emerging technologies and trends driving growth in minimally invasive cancer treatments
Published on Feb. 9, 2026
Got story updates? Submit your updates here. ›
The global Tumor Ablation Market is expected to reach $2,079.2 million by 2031, growing at a CAGR of 13.1% from 2024 to 2031. Innovations in radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and laser ablation, combined with advancements in image-guided therapy, are expanding the adoption of these minimally invasive cancer treatments globally.
Why it matters
The rising prevalence of cancer worldwide, combined with a growing preference for outpatient and less invasive treatment options, is fueling the demand for tumor ablation technologies. Advancements in ablation techniques and integration with imaging modalities are improving treatment precision and patient outcomes, making tumor ablation an increasingly attractive alternative to traditional surgical interventions.
The details
The Tumor Ablation Market is segmented by technology, with radiofrequency ablation (RFA) holding the largest market share at 40%, followed by microwave ablation (MWA), cryoablation, and laser ablation. By application, liver tumors are the leading segment, accounting for 35% of market revenue in 2024, with lung, kidney, and bone tumors also seeing growing adoption. Hospitals are the largest end-user, driven by the adoption of advanced imaging and interventional radiology suites.
- The global Tumor Ablation Market was valued at $797.4 million in 2022.
- The market is projected to reach $2,079.2 million by 2031, growing at a CAGR of 13.1% from 2024 to 2031.
The players
Medtronic plc
A leading global medical device company that offers a diversified portfolio of ablation devices and has a robust R&D pipeline.
Boston Scientific Corporation
A major player in the tumor ablation market, having expanded its microwave ablation system approvals in 2024.
AngioDynamics, Inc.
A company that has invested heavily in cryoablation device development and global distribution.
Johnson & Johnson (Biosense Webster)
A multinational pharmaceutical and medical device company that has invested in research combining ablation with immunotherapy protocols.
Siemens Healthineers
A leading medical technology company that has partnered with a major cancer hospital network in Europe to deploy integrated ablation-imaging suites.
What’s next
Continued advancements in tumor ablation technologies, such as the integration of real-time imaging and AI-powered navigation systems, are expected to further improve treatment precision and patient outcomes, driving the market's growth in the coming years.
The takeaway
The Tumor Ablation Market is poised for significant expansion, driven by the rising prevalence of cancer, the growing preference for minimally invasive treatments, and the ongoing innovations in ablation technologies. As the market matures, we can expect to see increased adoption of these advanced cancer treatment modalities, particularly in developing regions with expanding healthcare infrastructure.
